Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Pharmaceutical Diagnostics"


10 mentions found


He increased his price target by $25 to $575, which suggests shares can jump about 20.9% over the next year. Rollins upgraded the stock to neutral from sell and upped his price target from $1.25 to $3.15 per share, which implies roughly 21.6% potential upside. Analyst Rick Wise initiated coverage of GE Healthcare with a buy rating and $100 price target, which suggests 22.7% upside. Analyst Rob Owens upgraded the global cybersecurity company to overweight from neutral and lowered his price target by $20 to $290, which implies 30.6% upside. Its price target of 1,200 Taiwanese dollars implies upside of 36.4%.
Persons: Morgan Stanley, Piper Sandler, Rob Sanderson, Sanderson, — Pia Singh, Michael Rollins, Rollins, Lumen, Rick Wise, Wise, CrowdStrike, Rob Owens, Owens, pare, Price, Charlie Chan, Chan, Fred Imbert Organizations: CNBC, Taiwan Semiconductor, Meta, Citi, Lumen Technologies, GE Healthcare, Delta Air Lines, Microsoft Locations: U.S
GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. Organic revenue growth was 1%. We saw a continued acceleration of Vizamyl doses delivered in the U.S. in the second quarter. This is still a small contributor to sales growth but gives us optimism about its sales potential over the next few years." As a result, we're lowering our total company full-year organic revenue growth guidance."
Persons: Philips, It's, Eli Lilly, GEHC, , Jay Saccaro, We're, Arduini, Peter Arduini, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: GE Healthcare, Management, Revenue, LSEG, General Electric, Philips, Siemens, Club, GE Healthcare YTD, GE Healthcare's, Care Solutions, Pharmaceutical Diagnostics, U.S, CNBC, Lightrocket, Getty Locations: China, Eisai, U.S
Check out the companies making headlines in midday trading: Delta Air Lines — The stock fell almost 5% after the airline issued a sales growth forecast for the third quarter that came in below expectations. The company also reported an almost 30% decrease in net income for the second quarter compared to a year ago. Shares of major airline stocks American Airlines and United Airlines also fell around 4.7% and 3.7%, respectively, following the results. WD-40 reported total net sales of $155 million in the fiscal third quarter, up 9% from the year-ago period. Semiconductor names — Investors took a few chips off the table on Thursday, selling high-flying semiconductor stocks.
Persons: QuantumScape, Conagra, Lantheus, Tesla, Horton, , Alex Harring, Samantha Subin, Yun Li, Lisa Kailai Han, Pia Singh, Tanaya Macheel, Darla Mercado Organizations: Delta Air Lines, American Airlines and United Airlines, Costco, Peugeot, Opel, Vauxhall, Lantheus Holdings, Medicare, Services, PepsiCo, Revenue, Bloomberg News, Bloomberg, Industries, Builders, Semiconductor, , VanEck Semiconductor, Nvidia Locations: U.S, Canada, Europe
GE Healthcare shares sank Tuesday after the company's first-quarter sales and profits fell slightly short of the Wall Street consensus. GE Healthcare Why we own it : GE Healthcare is the global leader in medical imaging, diagnostics, and digital solutions in health care. That's what we have to say about this GE Healthcare quarter. This contributed to some of the softness in the first quarter quarter. The GE Healthcare scanner is called the Revolution CT. Martin Schutt | picture alliance | Getty Images
Persons: didn't, GE Healthcare's, , it's, Peter Arduini, Jim Cramer's, Jim Cramer, Jim, Martin Schutt Organizations: GE Healthcare, LSEG, General Electric, Philips, Siemens, GE Healthcare YTD, GE, Management, Alzheimer's, CNBC, Getty Locations: China, Covid, Jena , Germany
Business at GE Healthcare Technologies capped off 2023 on a strong note despite ongoing concerns about China. The quarterly earnings result from GE Healthcare on Tuesday is the best of both worlds. Quarterly commentary In addition to the mid-single-digit organic revenue growth, total company orders increased by 3%. The continued divergence in orders between the two companies suggests GE HealthCare is taking market share in the industry. A GE Healthcare Ltd. BioProcess machine stands on display during the International Pharmaceutical Expo (Interphex) in New York.
Persons: Eli Lilly, GEHC, It's, Jim Cramer, Philips, we're, GEHC's, We're, Jim Cramer's, Jim Organizations: GE Healthcare Technologies, The, Starbucks, GE Healthcare, General Electric, GE HealthCare, Management, JPMorgan Healthcare, Federal Reserve, CNBC, GE Healthcare Ltd, International Pharmaceutical, Bloomberg, Getty Locations: China, ultrasounds, MRIs, New York
A logo is displayed on a GE digital anesthesia carestation as U.S. Vice President Mike Pence (not pictured) visits a GE Healthcare manufacturing facility during the global coronavirus disease (COVID-19) outbreak in Madison, Wisconsin, U.S. April 21, 2020. Larger peer Abbott Laboratories (ABT.N) also topped its quarterly profit estimates, aided by a recovery in sales of its medical devices such as heart valves and pacemakers. In the previous quarter, GE HealthCare had said that Alzheimer's-related testing would help drive demand for its imaging equipment at hospitals and medical centers next year. $2.64 billion of the sales came from imaging devices, in line with estimates. On an adjusted basis, GE HealthCare earned 99 cents per share, above LSEG estimates of 90 cents.
Persons: Mike Pence, Daniel Acker, Christy Santhosh, Maju Samuel Organizations: GE, GE Healthcare, REUTERS, GE HealthCare Technologies Inc, Abbott Laboratories, GE HealthCare, Thomson Locations: Madison , Wisconsin, U.S, COVID, United States, Bengaluru
July 25 (Reuters) - GE HealthCare Technologies Inc (GEHC.O) raised its annual profit forecast on Tuesday, after beating quarterly earnings estimates due to easing supply chain issues that had largely impacted electronic components during the pandemic. Johnson & Johnson (JNJ.N) and Abbott Laboratories (ABT.N), which make medical devices like heart stents and implants, surpassed quarterly profit estimates last week as patients underwent their delayed procedures. GE HealthCare on Tuesday reported total quarterly sales of $4.8 billion, in line with analysts' estimates. Of this, $2.6 billion came from sales of imaging devices such as magnetic resonance imaging (MRI) and $839 million from ultrasound devices. The healthcare equipment firm operates four medical device businesses - imaging and ultrasound devices, patient care solutions and pharmaceutical diagnostics - with imaging being the largest.
Persons: Johnson, Khushi, Shailesh Organizations: GE HealthCare Technologies Inc, GE, Johnson, Abbott Laboratories, GE HealthCare, General Electric, Thomson Locations: Bengaluru
We're initiating a position in GE Healthcare (GEHC), buying 325 shares at roughly $79 each. GE Healthcare is the global leader in medical imaging, diagnostics, and digital solutions. GE Healthcare is one of the global leaders in Precision Diagnostics with an industry-leading injectable pharmaceutical portfolio in contrast media and molecular imaging. GE Healthcare is one of a few companies that offer a full suite of products and solutions to support patients. GEHC YTD mountain GE Healthcare YTD performance Analysts see GE Healthcare growing EPS to $4.33 in 2024, about a 15% increase from this year's outlook.
GE HealthCare shares rise in market debut
  + stars: | 2023-01-04 | by ( ) www.reuters.com   time to read: +1 min
Jan 4 (Reuters) - Shares of GE HealthCare Technologies Inc reversed course to trade up 4.4% in their market debut on Wednesday, after the medical equipment maker completed its separation from industrial conglomerate General Electric Co (GE.N). GE said in 2021 it would split into three public companies to simplify its business, pare down debt and breathe life into battered shares. GE HealthCare - which will operate imaging and ultrasound devices, patient care solutions and pharmaceutical diagnostics businesses - expects its addressable markets will expand to $102 billion by 2025 from $84 billion in 2021. The company will be present in more than 160 countries and have about 51,000 employees worldwide, GE HealthCare said on Wednesday. Shares of the company, which is scheduled to release its fourth-quarter and full-year results on Jan. 30, were trading at $58.40 on the Nasdaq.
Dec 8 (Reuters) - General Electric Co's (GE.N) healthcare division is aiming to have a medium-term organic revenue growth in the mid-single-digits, the unit's Chief Executive Officer Peter Arduini said at an investor day conference on Thursday. China, which accounts for about 15% of total GE Healthcare sales, would also help drive growth as there is a pent-up demand in the market, Arduini said. GE Healthcare also expects medium-term adjusted core earnings margin to be close to 20%. Zodl highlighted challenges such as macroeconomic factors, supply chain challenges, restructuring action undertaken in 2022 along with planned investment in research and development which may weigh on its core earnings margin. The healthcare company had revenue of around $18 billion last year, with about half of it from recurring sources, GE Healthcare said in a presentation.
Total: 10